PREVIOUS
✖
New Treatment for Crohn’s Disease
January 1 , 2025
3 days
126
0
- About 10 million people globally live with the inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease.
- Mirikizumab is a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis.
- Researchers revealed that, the long-term efficacy and safety of Mirikizumab for not only ulcerative colitis, but also Crohn’s disease.
- Inflammation from ulcerative colitis and Crohn’s disease can lead to disruptive symptoms.
Leave a Reply
Your Comment is awaiting moderation.